Jan Lycke

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 896 citations

Neurological Disorder, Clinical Neurology, Clinical Trials +9

A multicentre validation study of the diagnostic value of plasma neurofilament light

Nicholas J. Ashton, Shorena Janelidze, Ahmad Al Khleifat et al. · Nature Communications · 2021 · 528 citations · Full text

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies

Gustavo Luna, Peter Alping, Joachim Burman et al. · JAMA Neurology · 2019 · 492 citations · Full text

Monitoring disease activity in multiple sclerosis using serum neurofilament light protein

Lenka Novakova, Henrik Zetterberg, Peter Sundström et al. · Neurology · 2017 · 409 citations · Full text

Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study

Anna He, B. Merkel, J William L Brown et al. · The Lancet Neurology · 2020 · 401 citations · Full text

Disease Progression, Neurological Disorder, Clinical Epidemiology +7